top of page
Zerpidio Registered Logo.png
Zerpidio Image Content-09 1
SQ-NSCLC - Fight gambar copy.webp

Zerpidio can help you fighting
ES-SCLC

What is the Extensive-Stage Small Cell Lung Cancer ?

Lung cancer develops when cells in the lungs grow abnormally and uncontrollably, presenting a serious and potentially fatal health condition. This disease stands as a major global health burden, leading cancer-related deaths worldwide with GLOBOCAN 2020 data revealing approximately 1.8 million deaths (18% of all cancer mortality) in 2020.¹

Clinically, lung cancer is divided into two primary histological categories: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). These types are diagnosed based on how the cells look under a microscope.²

SCLC is characterized by its aggressive growth pattern, appearing as small oval-shaped cells under microscopic examination, with a high tendency to spread to other body tissues. In extensive stage SCLC, the cancer has already metastasized beyond its original lung to other body regions.³

More PatientLive Longer

In a clinical trial of ZERPIDIO with chemotherapy (carboplatin and etoposide) that included 585 patients with extensive-stage small cell lung cancer lived longer with Zerpidio + chemotherapy.³

Zerpidio updated untuk website.png

ES-SCLC : Extensive-Stage Small Cell Lung Cancer | OS : Overall Survival | PFS : Progressive Free Survival | HR : Hazard Ratio | CE: Carboplatin + Etoposide

Zerpidio combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer reduced the risk of death by 39%.³
icon 3
References
  1. https://www.who.int/news-room/fact-sheets/detail/lung-cancer

  2. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/extensive-stage-small-cell-lung-cancer

  3. Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study

Chen's Journey with Zerpidio

See how the support of the people who love her helps Chen stay positive and determined as they face squamous small cell lung cancer together.

Juan Journey with Zerpidio

See how the support of the people who love her helps Chen stay positive and determined as they face squamous small cell lung cancer together.

More Patient Journey

story journey pasien copy.webp

Important Safety Information


Tell your doctor if:

  • You have a history of :

    • Allergic reaction to other monoclonal antibody therapies

    • Kidney damage

    • Autoimmune disease

    • Organ transplant

    • Lung problems or breathing problems

    • Liver problems

  • You are pregnant or plan to become pregnant

  • You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.


Tell your doctor or nurse immediately if you have any signs or symptoms below:

  • Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;

  • Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;

  • Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;

  • Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;

  • Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;

  • Inflammation of the kidneys: decrease in the amount of urine you pass;

  • Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;

  • Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;

  • Inflammation of the eyes;

  • Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;

  • Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;

  • Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;

  • Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)

  • Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.

Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.


The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.


The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.


​The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.

These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.


​Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.

  • Badan POM-Approved Indications

    Serplulimab is approved by BPOM Indonesia for ES-SCLC and Sq-NSCLC

    NMPA-Approved Indications

    Serplulimab is approved by NMPA China for MSI-H solid tumors, Sq-NSCLC, ES-SCLC, and ESCC

    EMA-Approved Indications

    Serplulimab is approved by the European Medicines Agency (EMA) for ES-SCLC

    FDA-Approved as orphan drug

    Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for ES-SCLC

    Thai FDA-Approved Indications

    Serplulimab is approved by Thai FDA for ES-SCLC and Sq-NSCLC

    NPRA-Approved Indications

    Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for ES-SCLC

    HSA SG-Approved Indications

    Serplulimab is approved by Health Science Authority (HSA) for ES-SCLC

  • Tell your doctor if:

    • You have a history of :

      • Allergic reaction to other monoclonal antibody therapies

      • Kidney damage

      • Autoimmune disease

      • Organ transplant

      • Lung problems or breathing problems

      • Liver problems

    • You are pregnant or plan to become pregnant

    • You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.


    Tell your doctor or nurse immediately if you have any signs or symptoms below:

    • Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;

    • Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;

    • Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;

    • Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;

    • Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;

    • Inflammation of the kidneys: decrease in the amount of urine you pass;

    • Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;

    • Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;

    • Inflammation of the eyes;

    • Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;

    • Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;

    • Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;

    • Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)

    • Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.

    Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.


    The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.


    The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.


    ​The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.

    These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.


    ​Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.


    Important Safety Information


  • Badan POM-Approved Indications

    Serplulimab is approved by BPOM Indonesia for ES-SCLC and Sq-NSCLC

    NMPA-Approved Indications

    Serplulimab is approved by NMPA China for MSI-H solid tumors, Sq-NSCLC, ES-SCLC, and ESCC

    EMA-Approved Indications

    Serplulimab is approved by the European Medicines Agency (EMA) for ES-SCLC

    FDA-Approved as orphan drug

    Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for ES-SCLC

    Thai FDA-Approved Indications

    Serplulimab is approved by Thai FDA for ES-SCLC and Sq-NSCLC

    NPRA-Approved Indications

    Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for ES-SCLC

    HSA SG-Approved Indications

    Serplulimab is approved by Health Science Authority (HSA) for ES-SCLC


  • Important Safety Information


    Tell your doctor if:

    • You have a history of :

      • Allergic reaction to other monoclonal antibody therapies

      • Kidney damage

      • Autoimmune disease

      • Organ transplant

      • Lung problems or breathing problems

      • Liver problems

    • You are pregnant or plan to become pregnant

    • You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.


    Tell your doctor or nurse immediately if you have any signs or symptoms below:

    • Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;

    • Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;

    • Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;

    • Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;

    • Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;

    • Inflammation of the kidneys: decrease in the amount of urine you pass;

    • Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;

    • Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;

    • Inflammation of the eyes;

    • Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;

    • Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;

    • Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;

    • Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)

    • Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.

    Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.


    The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.


    The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.


    ​The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.

    These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.


    ​Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.

bottom of page